BLCM
Income statement / Annual
Last year (2022), Bellicum Pharmaceuticals, Inc.'s total revenue was $1.50 M,
a decrease of 75.81% from the previous year.
In 2022, Bellicum Pharmaceuticals, Inc.'s net income was -$24.97 M.
See Bellicum Pharmaceuticals, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
FY-2013
|
| Period Ended |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
12/31/2013 |
| Operating Revenue |
$1.50 M
|
$6.20 M
|
$500,000.00
|
$7.14 M
|
$1.12 M
|
$185,000.00
|
$388,000.00
|
$282,000.00
|
$1.78 M
|
$1.94 M
|
| Cost of Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Gross Profit |
$1.50 M |
$6.20 M |
$500,000.00 |
$7.14 M |
$1.12 M |
$185,000.00 |
$388,000.00 |
$282,000.00 |
$1.78 M |
$1.94 M |
| Gross Profit Ratio |
1 |
1 |
1 |
1 |
1 |
1 |
1 |
1 |
1 |
1 |
| Research and Development
Expenses |
$22.76 M
|
$23.58 M
|
$39.05 M
|
$64.54 M
|
$71.15 M
|
$65.66 M
|
$51.26 M
|
$33.56 M
|
$11.01 M
|
$7.05 M
|
| General & Administrative
Expenses |
$5.72 M
|
$7.01 M
|
$15.53 M
|
$29.97 M
|
$25.43 M
|
$21.91 M
|
$17.51 M
|
$15.86 M
|
$5.40 M
|
$2.81 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$5.72 M
|
$7.01 M
|
$15.53 M
|
$29.97 M
|
$25.43 M
|
$21.91 M
|
$17.51 M
|
$15.86 M
|
$5.40 M
|
$2.81 M
|
| Other Expenses |
$0.00 |
$7,000.00 |
$112,000.00 |
-$2.99 M |
$436,000.00 |
$864,000.00 |
$580,000.00 |
$3.18 M |
$43.21 B |
$0.00 |
| Operating Expenses |
$28.48 M |
$30.59 M |
$54.58 M |
$94.51 M |
$96.59 M |
$87.57 M |
$68.77 M |
$49.42 M |
$16.41 M |
$9.86 M |
| Cost And Expenses |
$28.48 M |
$30.59 M |
$54.58 M |
$94.51 M |
$96.59 M |
$87.57 M |
$68.77 M |
$49.42 M |
$16.41 M |
$9.86 M |
| Interest Income |
$0.00 |
$32,000.00 |
$387,000.00 |
$1.35 M |
$1.64 M |
$1.06 M |
$909,000.00 |
$641,000.00 |
$34,975.00 |
$3,921.00 |
| Interest Expense |
$46.00 |
$4,000.00 |
$2.66 M |
$4.28 M |
$4.20 M |
$3.67 M |
$1.76 M |
$12,000.00 |
$1.76 M |
$50,719.00 |
| Depreciation &
Amortization |
-$1.95 M
|
$517,000.00
|
-$1.89 M
|
$19.19 M
|
$6.70 M
|
$3.56 M
|
$2.31 M
|
$1.20 M
|
$666,607.00
|
$587,248.00
|
| EBITDA |
-$26.98 M
|
-$24.35 M
|
$2.39 M
|
-$87.36 M
|
-$95.47 M
|
-$82.77 M
|
-$68.38 M
|
-$47.30 M
|
-$57.84 B
|
-$7.33 M
|
| EBITDA Ratio |
-19.29 |
-3.93 |
-107.17 |
-9.54 |
-85.24 |
-447.39 |
-176.24 |
-167.71 |
-8.22 |
-3.78 |
| Operating Income Ratio
|
-17.99
|
-4.01
|
-103.38
|
-12.23
|
-85.24
|
-472.36
|
-176.24
|
-174.24
|
-32.49
|
-4.08
|
| Total Other
Income/Expenses Net |
$2.01 M
|
$15.16 M
|
-$10.11 M
|
-$25.11 M
|
-$2.57 M
|
-$4.39 M
|
-$861,000.00
|
$587,000.00
|
-$26.13 M
|
-$46,798.00
|
| Income Before Tax |
-$24.97 M |
-$9.71 M |
-$7.72 M |
-$112.48 M |
-$98.04 M |
-$91.78 M |
-$69.24 M |
-$48.55 M |
-$83.97 M |
-$7.97 M |
| Income Before Tax Ratio
|
-16.65
|
-1.57
|
-15.44
|
-15.75
|
-87.53
|
-496.1
|
-178.46
|
-172.16
|
-47.17
|
-4.11
|
| Income Tax Expense |
$2,000.00 |
-$127,000.00 |
$897,000.00 |
$13.62 M |
$1.63 M |
$3.67 M |
-$1.46 M |
$12,000.00 |
$1.09 M |
$3,921.00 |
| Net Income |
-$24.97 M |
-$9.58 M |
-$8.62 M |
-$126.09 M |
-$98.04 M |
-$91.78 M |
-$69.24 M |
-$48.55 M |
-$83.97 M |
-$7.97 M |
| Net Income Ratio |
-16.65 |
-1.54 |
-17.24 |
-17.65 |
-87.53 |
-496.1 |
-178.46 |
-172.16 |
-47.17 |
-4.11 |
| EPS |
-0.81 |
-0.83 |
-1.5 |
-26.92 |
-24.37 |
-28.94 |
-25.69 |
-18.43 |
-33.47 |
-8.11 |
| EPS Diluted |
-0.81 |
-0.83 |
-1.5 |
-26.92 |
-24.37 |
-28.94 |
-25.69 |
-18.43 |
-33.47 |
-8.11 |
| Weighted Average Shares
Out |
$30.83 M
|
$11.50 M
|
$5.76 M
|
$4.68 M
|
$4.02 M
|
$3.17 M
|
$2.70 M
|
$2.63 M
|
$2.51 M
|
$982,776.00
|
| Weighted Average Shares
Out Diluted |
$30.83 M
|
$11.50 M
|
$5.76 M
|
$4.68 M
|
$4.02 M
|
$3.17 M
|
$2.70 M
|
$2.63 M
|
$2.51 M
|
$982,776.00
|
| Link |
|
|
|
|
|
|
|
|
|
|
